Randomized Phase II Study Comparing Gemcitabine/S-1 Combination Chemoradiotherapy With Gemcitabine/S-1 Combination Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer.
When cancer develops outside of the pancreas from within the anatomical placement of the
pancreas itself, it becomes difficult to excise in most cases. Generally, most pancreatic
cancers are already unresectable at the time of diagnosis when we have recognized
infiltration of over 1/2 the circumference of major arteries such as the celiac artery and
super mesenteric artery in particular.
In comparison with advanced pancreatic cancer with distant metastases, it is not easy to
treat unresectable locally advanced pancreatic cancer, even when performing standard
gemcitabine monotherapy. In the case of unresectable locally advanced pancreatic cancers
without distant metastases, we are left with the choice of whether or not to perform
radiation therapy. This decision remains unsolved worldwide, despite the continuing efforts
of researchers to bring an end to the clinical doubt.
We will report our results as well as the problems of combining treatments with
chemoradiotherapy, using the novel anticancer agent gemcitabine as well as/or S-1, not 5FU,
predominantly from our own clinical trials on this occasion.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Two year survival rate
Tatsuya Ioka, MD
Osaka Medical Center for Cancer and CVD
Japan: Institutional Review Board